"Platinum" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
| Descriptor ID |
D010984
|
| MeSH Number(s) |
D01.268.556.690 D01.268.956.734 D01.552.544.690
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Platinum".
Below are MeSH descriptors whose meaning is more specific than "Platinum".
This graph shows the total number of publications written about "Platinum" by people in this website by year, and whether "Platinum" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 1 | 4 |
| 2013 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 2 | 4 | 6 |
| 2017 | 4 | 1 | 5 |
| 2018 | 1 | 1 | 2 |
| 2020 | 2 | 5 | 7 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platinum" by people in Profiles.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15; 130(10):1747-1757.
-
SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation. Commun Biol. 2024 01 09; 7(1):67.
-
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463.
-
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Res Treat. 2023 Nov; 202(1):191-201.
-
Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy. 2023 03; 15(4):293-309.
-
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol. 2022 Dec; 167(3):404-413.
-
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 08 10; 40(23):2568-2577.
-
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer. 2022 08; 127(3):569-576.
-
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemother Pharmacol. 2022 05; 89(5):721-735.